PabloValdez

English105
Nov/15/2016
StephanieMaherPalenque,M.A.

Impact of New ADHD Treatments

Disorder attention deficit with hyperactivity (ADHD) is one of the disorders

neurobiological more common in childhood, characterized by the existence of inappropriate

levels of inattention, hyperactivity, or impulsivity. This affects the prevalence in school-age

children, being able to extend during adolescence even in cases and symptoms continue into

adulthood.
ADHD has a very strong negative impact on the individual, extending to all areas of life.

Due to the symptoms of the disorder, which can be added to the other symptoms associated with

it, patients are psychologically affected, in their academic performance, family and social

relationships, as well as work area, as demonstrated by a recent American epidemiological study

have a greater possibility of suffering accidents, abusing substances or having problems with the

law; In line, their quality of life and self-esteem may be greatly diminished. The economic cost

associated with the disorder is high and not only due too medical or health costs, but also to

indirect costs resulting from loss of labor productivity, legal problems or educational

repercussions.
The treatment reduces the negative impact of the disorder on these areas and in many

cases determines that they will not be affected, so that the establishment of a personalized

therapeutic plan is determinant in individuals with ADHD.

The comprehensive approach to the treatment of patients with ADHD incorporates

pharmacological, psychological, psychoeducational, etc. treatments. The decision to use

pharmacotherapy. Be based on an adequate diagnostic process, with a special evaluation of the

symptoms that cause functional deterioration and the area in which the patient develops. The

participation of patients and their parents, as well as information and collaboration of teachers, is

important in establishing the most appropriate therapy according to individual circumstances and

facilitate therapeutic compliance.

Pharmacological treatment should be linked to psychosocial treatments that contribute to

reducing residual dysfunctionality. The combination of both forms of treatment is called

multimodal therapy and is more effective than isolated psychosocial treatment; beneficial effects

on the symptoms surrounding ADHD and its functional impact are observed.
To assess whether a drug is effective requires previously and individually define the goals

for the patient both short and long term. These drugs usually control the clinically more striking

symptomatology, although the persistence of symptoms or manifestations is less apparent but

may have important functional significance. Therefore, defining what should be understood by

inadequate response or lack of improvement is one of the most relevant aspects to improve the

prognosis of patients
Although in general the drugs used are safe, effective and well tolerated, some moderate

adverse effects may lead to patients diminishing their adherence to them, especially in the

adolescent group. The variability in the occurrence of adverse effects, which could be due to the

different pharmacokinetics of the different pharmacological presentations, may influence the

patients 'or their parents' subjective perception of the usefulness of the drug and compromise

adherence to the drug.

From an already my point of view, there are different circumstances that may make

consider that the patient does not respond optimally or achieving clinical remission.

CONCLUSIONS
 There is a high variability in the effect of medications for ADHD. The efficacy of short-

acting and long-acting stimulants does not differ greatly in clinical trials, although both groups

do provide significantly better efficacy data than non-stimulants.

Differences in effect size and other characteristics (lower number of doses per day, longer

duration of action) translate into cost differences when treating large numbers of patients.

Reference:

Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in
the United States: results from the National Comorbidity Survey Replication. Am J
Psychiatry 2006; 163: 716-723.

Pieiro-Dieguez B, Balanz-Martnez V, Garca-Garca P, et al. Psychiatric Comorbidity

at the Time of Diagnosis in Adults With ADHD: The CAT Study. J Atten Disord 2014; 1-
10.
 Steinhausen HC, Nvik TS. ADORE Study Group. Co-existing psychiatric problems in
ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006; 15: i25-i29.

Friedrichs B, Igl W, Larsson H, et al. Coexisting psychiatric problems and stressful life
events in adults with symptoms of ADHD--a large Swedish population-based study of
twins. J Atten Disord 2012; 16: 13-22.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental

Disorders, Fifth Edition. 2013.

Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three
decades: an updated systematic review and meta-regression analysis. Int J Epidemiol
2014; 43: 434-442.

Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit

hyperactivity disorder worldwide. Eur J Pediatr 2007; 166: 117-123.